Table 1. Patient demographics.
| Variables | Robotic (n=12) | |
|---|---|---|
| Age | 72.5 (54–85) | |
| BMI (kg/m2) | 23.35 (17.53–41.28) | |
| Medical co-morbid condition | ||
| Yes | 10 (83.3) | |
| Previous abdominal/pelvic surgery | ||
| Yes | 9 (75) | |
| ASA score | ||
| 2 | 0 | |
| 3 | 12 (100) | |
| 4 | 0 | |
| CA-125 at diagnosis (UI/mL) | 931 (264–6,987) | |
| Pre-operative CA-125 (UI/mL) | 14 (5–240) | |
| RECIST tumor response | ||
| Complete | 1 (8.3) | |
| Partial | 9 (75) | |
| Stable | 1 (8.3) | |
| No. of cycles of NACT | 3.5 (3–6) | |
| No. of cycles of adjuvant chemotherapy | 2.5 (0–4) | |
| Type of chemotherapy | ||
| Carboplatin-paclitaxel every 3 weeks | 11 (91.7) | |
| Carboplatin-paclitaxel every week | 1 (8.3) | |
| Carboplatin-paclitaxel-bevacizumab every 3 weeks | 0 | |
| BRCA status | ||
| No pathogenic variant | 9 (75) | |
| BRCA1 | 2 (17) | |
| BRCA2 | 0 (0) | |
| Unknown | 1 (8) | |
| Histology | ||
| Serous | 12 (100) | |
| Clear cell | 0 | |
| Carcinosarcoma | 0 | |
| Mucinous | 0 | |
| High grade | ||
| Yes | 12 (100) | |
Values are presented as median (range) or number (%).
BMI, body mass index; ASA, American Society of Anesthesiologists; NACT, neoadjuvant chemotherapy; CA-125, cancer antigen 125; RECIST, response evaluation criteria in solid tumors.